Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when OSCR files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsOscar Health co-founder Mario Schlosser steps down as CTO, transitions to advisory role
Filed June 2, 2026 · Period ending May 29, 2026 · ~1 min read
Key Changes
-
high
Mario Schlosser, co-founder and CTO, is stepping down from operational leadership to become Co-Founder & Advisor to CEO effective June 1, 2026, focusing on AI and digital health while remaining on the Board.
Item 5.02 verify on EDGAR → -
medium
Schlosser's compensation drops to $370,000 base salary with no annual bonus eligibility or new equity grants going forward, though existing equity awards continue vesting.
Item 5.02 verify on EDGAR → -
low
The new advisory agreement eliminates severance payments and company-subsidized healthcare benefits upon any termination of employment.
Item 5.02 verify on EDGAR →
Summary
Oscar Health announced that co-founder Mario Schlosser is stepping back from day-to-day operations, transitioning from President of Technology and Chief Technology Officer to an advisory role. Effective June 1, 2026, Schlosser will serve as Co-Founder & Advisor to the CEO, focusing on AI and digital health initiatives while maintaining his Board seat.
This represents a significant leadership change for the health insurance technology company, as Schlosser has been a key architect of Oscar's technology platform since its founding. The transition comes with a substantial reduction in compensation. Schlosser's base salary drops to $370,000 annually, and he will no longer receive annual bonuses or new equity grants, though his existing equity awards continue vesting.
The agreement also eliminates severance protections typical of executive contracts. For investors, the key question is whether Oscar's technology leadership bench is deep enough to maintain innovation momentum without Schlosser in an operational role. Watch for any announcements about who will assume the CTO responsibilities and how the company's product roadmap evolves in coming quarters.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
Mario Schlosser entered into an amended and restated employment agreement (the “A&R Employment Agreement”), effective as of June 1, 2026 (the “Effective Date”), in connection with Mr. Schlosser’s transition from President of Technology and Chief Technology Officer of the Company to Co-Founder & Advisor to the CEO.
Mario Schlosser, a co-founder, is stepping down from his operational roles as President of Technology and Chief Technology Officer to become an advisor to the CEO. He will focus on AI and digital health initiatives while remaining on the Board of Directors. This represents a significant reduction in day-to-day operational responsibilities for a key executive.
Added in current filing · verify on EDGAR →
Mr. Schlosser’s annual base salary will be $370,000, effective as of the Effective Date.
Schlosser's new base salary is set at $370,000 annually starting June 1, 2026. This reflects his transition to an advisory role with reduced operational responsibilities compared to his previous executive positions.
Added in current filing · verify on EDGAR →
Commencing with calendar year 2026, Mr. Schlosser will no longer be eligible to receive an annual bonus under the Company’s annual bonus program. ... Mr. Schlosser will not be eligible to receive any long-term incentive or equity-based compensatory awards during the term of the A&R Employment Agreement, but will continue to vest in the equity awards previously granted to him in accordance with their terms.
Schlosser will no longer receive annual bonuses or new equity grants going forward, though his existing equity awards will continue vesting. This significantly reduces his total compensation package and aligns with his advisory rather than executive role.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 2, 2026 · How we verify